BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 11786079)

  • 1. Immunoglobulin light chain amyloidosis and the kidney.
    Gertz MA; Lacy MQ; Dispenzieri A
    Kidney Int; 2002 Jan; 61(1):1-9. PubMed ID: 11786079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
    Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
    Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2016 Sep; 91(9):947-56. PubMed ID: 27527836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
    Sezer O; Schmid P; Shweigert M; Heider U; Eucker J; Harder H; Sinha P; Radtke H; Possinger K
    Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary systemic amyloidosis.
    Comenzo RL
    Curr Treat Options Oncol; 2000 Apr; 1(1):83-9. PubMed ID: 12057064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)].
    Adam Z; Nedbálková M; Krejcí M; Pour L; Husek K; Veselý K; Cermáková Z; Krivanová A; Mayer J; Hájek R
    Vnitr Lek; 2010 Mar; 56(3):240-6. PubMed ID: 20394211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of AL amyloidosis.
    Sezer O; Eucker J; Jakob C; Possinger K
    Clin Nephrol; 2000 Jun; 53(6):417-23. PubMed ID: 10879660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Renal disease in multiple myeloma].
    Hiromura K; Nojima Y
    Nihon Rinsho; 2007 Dec; 65(12):2229-34. PubMed ID: 18069265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary systemic amyloidosis.
    Gertz MA; Rajkumar SV
    Curr Treat Options Oncol; 2002 Jun; 3(3):261-71. PubMed ID: 12057072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Light chain amyloidosis--clinical symptoms, update diagnosis, and treatment].
    Charliński G; Jurczyszyn A; Wiktor-Jedrzejczak W
    Przegl Lek; 2014; 71(2):102-9. PubMed ID: 25016786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloidosis: recognition, confirmation, prognosis, and therapy.
    Gertz MA; Lacy MQ; Dispenzieri A
    Mayo Clin Proc; 1999 May; 74(5):490-4. PubMed ID: 10319082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
    Comenzo RL; Vosburgh E; Simms RW; Bergethon P; Sarnacki D; Finn K; Dubrey S; Faller DV; Wright DG; Falk RH; Skinner M
    Blood; 1996 Oct; 88(7):2801-6. PubMed ID: 8839879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.
    Hernández-Reyes J; Galo-Hooker E; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Rev Invest Clin; 2012; 64(6 Pt 2):604-8. PubMed ID: 23593777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
    Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
    Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.
    Gertz MA
    Am J Hematol; 2011 Feb; 86(2):180-6. PubMed ID: 21264900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.